单中心溃疡性结肠炎患者2010至2019年用药趋势分析  

Analysis of the trend of medication use in patients with ulcerative colitis in a single center from 2010 to 2019

作　　者：薛鲜敏 苏松 周禾 张玉洁 王家瑶 金熠蓉 时永全 吴开春 梁洁 Xue Xianmin;Su Song;Zhou He;Zhang Yujie;Wang Jiayao;Jin Yirong;Shi Yongquan;Wu Kaichun;Liang Jie(Department of Gastroenterology,Xijing Hospital,Air Force Medical University,Xi′an 710032,China)

机构地区：[1]空军军医大学西京医院消化内科,西安710032

出　　处：《中华消化杂志》2021年第9期624-628,共5页Chinese Journal of Digestion

基　　金：国家自然科学基金(81772650,81322037,81421003)。

摘　　要：目的分析近10年空军军医大学西京医院消化内科溃疡性结肠炎(UC)患者的用药趋势。方法回顾性收集2010至2019年空军军医大学西京医院消化内科1425例UC确诊患者的临床资料,根据用药时间段将UC患者分为2010至2014年组和2015至2019年组,分析2组UC患者的一般情况和用药趋势,再分别根据患者性别和年龄(<40岁和≥40岁)进行亚组分析。统计学方法采用独立样本t检验和卡方检验。结果2010至2014年组和2015至2019年组的UC患者数分别为369和1056例,缓解患者分别占9.5%(35/369)和12.0%(127/1056),轻度患者分别占40.4%(149/369)和41.6%(439/1056),中度患者分别占37.4%(138/369)和28.9%(305/1056),重度患者分别占12.7%(47/369)和17.5%(185/1056)。2010至2014年组不同程度的UC患者比例与2015至2019年组患者比较差异无统计学意义(P>0.05)。2010至2014年组与2015至2019年组的患者年龄和女性比例[(46.2±15.3)岁比(44.6±30.6)岁,45.8%(169/369)比44.8%(473/1056)]比较差异均无统计学意义(P均>0.05)。2015至2019年组患者5-氨基水杨酸(5-ASA)、糖皮质激素、免疫抑制剂和生物制剂的使用率均高于2010至2014年组[分别为96.8%(1022/1056)比90.0%(332/369)、29.9%(316/1056)比14.6%(54/369)、8.4%(89/1056)比2.4%(9/369)、4.8%(51/1056)比0.5%(2/369)],差异均有统计学意义(χ^(2)=26.766、33.256、15.315、14.038,P均<0.01)。2010至2014年组与2015至2019年组组内女性和男性UC患者的年龄、5-ASA、糖皮质激素、免疫抑制剂和生物制剂的使用率[(47.2±13.6)岁比(45.3±16.5)岁、(43.1±12.9)岁比(45.8±39.5)岁,88.8%(150/169)比91.0%(182/200)、96.8%(458/473)比96.7%(564/583),13.6%(23/169)比15.5%(31/200)、28.3%(134/473)比31.2%(182/583),2.4%(4/169)比2.5%(5/200)、7.0%(33/473)比9.6%(56/583),0比1.0%(2/200)、5.3%(25/473)比4.5%(26/583)]比较差异均无统计学意义(P均>0.05)。2010至2014年组年龄≥40岁的患者中,女性比例高于年龄<40岁的患者[50.2%(121/241)比37.5%(48/128)],5-ASA使Objective To analyze the trend of medication use in patients with ulcerative colitis(UC)in recent ten years in at Xijing Hospital,Air Force Military Medical University.Methods From 2010 to 2019,the clinical data of 1425 patients diagnosed with UC in the Department of Gastroenterology at Xijing Hospital,Air Force Medical University,were retrospectively collected.According to the period of medication,the UC patients were divided into year 2010 to 2014 group and year 2015 to 2019 group.The general information and the medication trend of year 2010 to 2014 group and year 2015 to 2019 group were analyzed.And then according to gender and age(<40 years old and≥40 years old),patients were divided into subgroups and analyzed.Independent sample t test and chi-square test were used for statistical analysis.Results The number of UC patients of year 2010 to 2014 group and year 2015 to 2019 group was 369 and 1056,respectively.The percentages of patients in remission of the two groups were 9.5%(35/369)and 12.0%(127/1056),respectively;the percentages of mild patients were 40.4%(149/369)and 41.6%(439/1056),respectively;the percentages of moderate patients were 37.4%(138/369)and 28.9%(305/1056),respectively;the percentages of severe patients were 12.7%(47/369)and 17.5%(185/1056),respectively.There was no significant difference in the proportion of UC patients with different degrees between year 2010 to 2014 group and year 2015 to 2019 group(P>0.05).There were no significant differences in the age and proportion of female between the year 2010 to 2014 group and year 2015 to 2019 group((46.2±15.3)years old vs.(44.6±30.6)years old;45.8%,169/369 vs.44.8%,473/1056;both P>0.05).The utilization rates of 5-aminosalicylic acid(5-ASA),glucocorticoid,immunosuppressants,and biological agents of the year 2015 to 2019 group were all higher than those of the year 2010 to 2014 group(96.8%,1022/1056 vs.90.0%,332/369;29.9%,316/1056 vs.14.6%,54/369;8.4%,89/1056 vs.2.4%,9/369;4.8%,51/1056 vs.0.5%,2/369,respectively),and the differences were all st

关 键 词：炎性肠疾病 结肠炎 溃疡性 十年 用药趋势 

分 类 号：R574.62[医药卫生—消化系统]